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Abstract
Hepatitis C virus (HCV) is the etiologic agent of chronic liver disease, hepatitis C. Spontaneous resolution of viral infection is
associated with vigorous HLA class I- and class II-restricted T cell responses to multiple viral epitopes. Unfortunately, only
20% of patients clear infection spontaneously, most develop chronic disease and require therapy. The response to
chemotherapy varies, however; therapeutic vaccination offers an additional treatment strategy. To date, therapeutic
vaccines have demonstrated only limited success. Vector-mediated vaccination with multi-epitope-expressing DNA
constructs alone or in combination with chemotherapy offers an additional treatment approach. Gene sequences encoding
validated HLA-A2- and HLA-DRB1-restricted epitopes were synthesized and cloned into an expression vector. Dendritic cells
(DCs) derived from humanized, HLA-A2/DRB1 transgenic (donor) mice were transfected with these multi-epitope-expressing
DNA constructs. Recipient HLA-A2/DRB1 mice were vaccinated s.c. with transfected DCs; control mice received non-
transfected DCs. Peptide-specific IFN-c production by splenic T cells obtained at 5 weeks post-immunization was quantified
by ELISpot assay; additionally, the production of IL-4, IL-10 and TNF-a were quantified by cytokine bead array. Splenocytes
derived from vaccinated HLA-A2/DRB1 transgenic mice exhibited peptide-specific cytokine production to the vast majority
of the vaccine-encoded HLA class I- and class II-restricted T cell epitopes. A multi-epitope-based HCV vaccine that targets
DCs offers an effective approach to inducing a broad immune response and viral clearance in chronic, HCV-infected
patients.
Citation: Mishra S, Lavelle BJ, Desrosiers J, Ardito MT, Terry F, et al. (2014) Dendritic Cell-Mediated, DNA-Based Vaccination against Hepatitis C Induces the Multi-
Epitope-Specific Response of Humanized, HLA Transgenic Mice. PLoS ONE 9(8): e104606. doi:10.1371/journal.pone.0104606
Editor: Eui-Cheol Shin, KAIST, Graduate School of Medical Science & Engineering, Republic of Korea
Received April 2, 2014; Accepted June 29, 2014; Published August 11, 2014
Copyright:  2014 Mishra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data files are available in the
Harvard Dataverse Repository with the DOI:10.7910/DVN/26674.
Funding: Supported by National Institutes of Health Research Grant U19 AI082642. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: Anne De Groot and William Martin are senior officers and majority shareholders at EpiVax, Inc. Matt Ardito and Frances Terry are also
employed at EpiVax, Inc. These authors acknowledge a potential conflict of interest and attest that the work contained in this report is free of any bias that might
be associated with the commercial goals of the company. There are no patents, products in development or marketed products to declare. This does not alter
their adherence to all the PLOS ONE policies on sharing data and materials.
* Email: sgregory@lifespan.org
Introduction
Hepatitis C virus (HCV), a small single-stranded RNA virus, is a
major cause of chronic liver disease. An estimated 180 million
people worldwide, ,3 million in the United States alone, are
infected [1–3]. The vast majority of those (80–85%) fails to clear
the virus spontaneously, most patients develop chronic hepatitis C
[4]. Hepatitis C is the underlying cause of ,25% cases of liver
cancer (WHO Media Center Report, 2012). Cirrhosis due to
chronic HCV is the leading indicator for liver transplantation in
the U.S. The socioeconomic burden of hepatitis C-associated
diseases in the U.S. is estimated at a staggering $7 billion/year [5].
Until recently, the standard of care for patients consisted of
pegylated-interferon and ribavirin administered over a 48-week
period, which results in a sustained virologic response (SVR) in
45–50% of those infected with HCV genotype 1 (the principal
causative agent in the US) [6]. New therapeutic approaches that
include direct-acting anti-viral agents, for example, NS3-4A
protease inhibitors (i.e., boceprevir or telaprevir) and NS5B
polymerase inhibitors (e.g., sofosbuvir), administered in various
combinations with or without pegylated-interferon or ribavirin,
increase the SVR significantly [7]. Unfortunately, the dosing
regimens can be complex, the adverse side effects occur frequently
and are often severe, the cost of treatment is high, and a significant
portion of treated population remains infected. Consequently, it
seems highly unlikely that these emerging treatment paradigms
will exert an immediate impact on the global distribution of HCV.
Additional treatment approaches are urgently needed.
The ability of a minority of patients to resolve acute HCV
infections spontaneously, and the capacity of some individuals to
eliminate virus in the absence of antibody production, suggest that
an effective, epitope-based therapeutic vaccine is a realistic goal.
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Development of such a vaccine has proven problematic, however,
due primarily to: infidelity of the viral RNA polymerase (NS5b),
genetic diversity and the rapid emergence of viral variants [8].
Thus, a safe and effective vaccine must elicit the vigorous
responses of both CD4+ and CD8+ T cells to conserved viral
epitopes, which contribute to the elimination of HCV without
causing liver pathology. Vaccine strategies undertaken to date,
however, have achieved varied and only limited success in clinical
trials [9,10]. Therapeutic vaccination with HCV epitope-express-
ing dendritic cells (DCs) concurrent with or without conventional
drug therapy offers a vector-mediated approach to treating
chronic, HCV-infected patients.
DCs play a central role in CD4+ and CD8+ T cell activation and
the induction of immunity [11]. The potential efficacy of DC
vector-mediated vaccines in treating chronic hepatitis C was
demonstrated in a recent Phase I clinical trial in which patients
vaccinated with autologous, monocyte-derived DCs pulsed with 6
HCV-specific, HLA-class I-restricted peptides exhibited peptide-
specific CD8 T cell responses [12,13]. These responses were not
sustained, however, and the effect on viral load was negligible
suggesting that HCV clearance requires vaccination with a
broader range of epitopes that includes those restricted by HLA
class II [12]. Toward this end, immunoinformatics tools were used
to predict 19 HLA-A*0201-restricted epitopes and 19 promiscu-
ous, HLA-DRB1-restricted immunogenic consensus sequences
(ICS, each composed of 5–28 epitopes), which were highly-
conserved among HCV genotypes 1a and 1b [14]. These
predicted epitopes/ICS exhibited HLA binding activity in
competitive binding assays and the ability to elicit the peptide-
specific responses of naı¨ve human T cell in vitro, thus validating
their immunogenicity [14]. In the experiments described herein,
the gene sequences that encode these peptides were incorporated
into multi-epitope-expressing DNA constructs; humanized, HLA-
A2/DRB1 transgenic mice were then vaccinated with these
constructs using DCs as a vector. Splenocytes prepared at 35 days
post-immunization exhibited peptide-specific IFN-c and TNF-a
production in response to the vast majority of the vaccine-encoded
HLA class I- and class II-restricted epitopes; IL-4 and IL-10
production was negligible.
Materials and Methods
Multi-HCV epitope DNA vaccine constructs
Essentially the entire human population expresses one or more
of a panel of the eight common HLA-DRB1 alleles: DRB1*0101,
*0301, *0401, *0701, *0801, *1101, *1301, and *1501; approx-
imately 50% expresses HLA-A*0201 [15,16]. Accordingly, 19
HLA-A*0201-restricted epitopes and 19 promiscuous, HLA-
DRB1-restricted ICS were predicted, synthesized as peptides,
and validated by demonstrating their HLA binding activity and
ability to elicit immune recognition by naı¨ve human T cells
in vitro [14]. These sequences are listed in Tables S1 and S2 in
File S1.
The sequences encoding these A2- and DRB1-restricted
epitopes/ICS were aligned in a ‘‘string-of-beads’’ conformation,
concatenated initially at random to form two multi-epitope genes:
DRB1 and A2 constructs. Epitope order was then optimized to
avoid creation of immunogenic sequences at epitope junctions
using VaccineCAD, an algorithm that iteratively re-arranges
epitopes [17]. Where VaccineCAD re-ordering was not sufficient
to reduce potential junctional immunogenicity, Ala-Ala-Tyr
proteasomal cleavage (Class I) or Gly-Pro-Gly-Pro-Gly spacer
(Class II) sequence was inserted between epitopes to optimize
processing [18].
A Kozak sequence (GCCGCCACCATGG) was engineered
upstream of the coding sequence to ensure efficient translation
initiation. For the DRB1 construct, the tissue plasminogen
Figure 1. Schematic: DC vector-mediated vaccination of HLA-A2/DR1 mice. Humanized HLA-A2/DRB1 transgenic mice were vaccinated s.c.
with multi-HCV epitope-expressing plasmids using DCs derived from transgenic mice administered Flt3L-secreting B16 melanoma cells as a vaccine
vector.
doi:10.1371/journal.pone.0104606.g001
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activator secretion sequence (QMSPALTCLVLGLALVF-
GEGSA) was inserted between the start codon and the multi-
epitope coding sequence to target the protein product to the
extracellular space and the MHC class II processing pathway. For
the A2 construct, a calreticulin sequence was inserted between the
start codon and the multi-epitope coding sequence to target the
protein product to the endoplasmic reticulum and the MHC Class
I processing pathway [19]. Finally, two stop codons were inserted
following the multi-epitope coding sequences to ensure efficient
translation termination. The two multi-epitope gene sequences
were synthesized by GenScript USA, Inc. (Piscataway, NJ) and
cloned into the NTC8685-eRNA41H-EGFP expression vector
(Nature Technology Corporation, Lincoln, NE).
Mice
A colony of humanized, HLA double-transgenic mice [HLA-
A2.1-/HLA-DRB1-transgenic H-2 class I/class II-knockout mice,
obtained from Dr. Y-C. Lone (Paris, France) [20], is currently
housed and bred under contract at Taconic Farms, Inc.,
Germantown, NY. Mice, housed in well-ventilated rooms
maintained at 22uC and an alternating 12-hour light and dark
cycle, were provided food and water ad libitum. All experiments
were conducted using female animals between 6 and 8 weeks of
age at the time of initiation.
Immunization
HLA-A2/DRB1 transgenic mice were immunized with the two
multi-epitope-expressing DNA constructs using DCs as a vector
according to the schematic shown in Figure 1. Briefly, 2–3 donor
mice were inoculated s.c. with 16107 FMS-related tyrosine kinase
3 ligand (Flt3L)-secreting B16 melanoma cells (gift obtained from
Dr. Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA),
which induced a dramatic expansion of the DC population in vivo
[21,22]. On day 12–14 post-inoculation, single cell splenocyte
suspensions were prepared and rendered erythrocytes-depleted by
ammonium chloride treatment. An enriched DC population was
obtained by positive selection using pan-DC (anti-CD11c and anti-
mPDCA-1) magnetic MicroBeads and the protocol provided by
the supplier (Miltenyi Biotec Inc., Auburn, CA). Subsequently,
these purified DCs were transfected with either the multi-epitope-
expressing A2 or DRB1 vaccine construct using the mouse
dendritic cell nucleofector kit, AMAXA 4D-Nucleofector System
and protocol provided (Lonza, Walkersville, MD). DCs obtained
from a new group of donor mice each time were transfected with
these two constructs and mixed in equal numbers just prior to
vaccinating recipient animals.
Groups of four recipient mice were inoculated s.c. at the base of
the tail at 2-week intervals with 26106 DCs transfected with the
HLA-A2 and HLA-DRB1 vaccine constructs; mice vaccinated
with 26106 non-transfected dendritic cells served as the control.
Spleens were dissected at 4–5 weeks post-immunization, and the
peptide-specific responses of T cells derived from vaccinated and
control mice were determined.
Flow cytometric analysis
The cell-surface markers expressed by the purified
CD11c+PDCA-1+ DCs were analyzed by flow cytometry using
the methods we described previously [23,24] and the following
panel of dye-conjugated monoclonal antibodies purchased from
BD Biosciences (San Jose, CA): CD8a (clone 53-6.7), CD11b
(clone M1/70), CD11c (clone HL3); CD40 (clone MH40-3),
CD45R/B220 (RA3-6B2), CD80 (clone 16-10A1), CD86 (clone
GL-1) and HLA-DR (clone L243). All staining was conducted in
the presence of saturating concentrations of anti-CD16/CD32
(Fcc III/II receptor-block, clone 2.4G2); appropriate rat, hamster,
and mouse IgG isotype matched controls were included in the
analyses to correct for non-specific staining. Flow cytometric
analyses were performed using a Becton Dickinson LSR-II flow
cytometer (BD Biosciences, San Jose, California) and analyzed
using FlowJo software (Tree Star, Inc., Ashland, OR).
ELISpot assays
Epitope-specific T lymphocytes were quantified using mouse
IFN-c ELISpot assay kits purchased from eBioscience, Inc. (San
Diego, CA) and the protocol provided. Triplicate wells were
inoculated with 50,000 splenocytes/200 ml serum-free, X-VIVO
15 medium (Lonza, Walkerville, MD) and 10 mg/ml single peptide
final concentration [100 mg/ml DMSO stock diluted to 1:1,000]
encoded by the vaccine constructs. Positive (phytohemagglutinin)
and negative (0.1% DMSO) controls were included. The number
of spots/well was quantified using a CTL-immunospot S5 UV
Analyzer (Cellular Technology Limited, Shaker Heights, OH).
Table 1. DCs derived from Flt3L-treated, HLA-A2/DRB1 mice exhibit an immature phenotypea.
Trait CD11c
+B2202 CD11c+B220+
(conventional; cDCs) (plasmacytoid; pDCs)
DCs/spleen 5.946107 0.656107
CD8+ 62.30% NDb
CD11b+ 47.00% ND
CD40+ 0.90% 8.10%
CD80+ 3.00% 15.10%
CD86+ 51.30% 24.40%
HLA-DR1+ 5.30% 6.40%
aCD11c+PDCA-1+ DCs, purified from 2.556108 splenocytes/HLA-A2/DRB1 transgenic mouse inoculated s.c. with Flt3L-secreting B16 myeloma cells 12 days previously,
were quantified and characterized by flow cytometry.
bNot determined.
doi:10.1371/journal.pone.0104606.t001
Epitope-Based HCV Vaccine
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Cytokine quantitation
Splenocytes (26105 cells)/200 ml X-VIVO 15 medium contain-
ing 10 mg/ml individual peptide/well in 96-well round bottom
plates were incubated for ,40 hours. The culture supernates were
collected at the end of the incubation period; IL-4, IL-10, TNF-a
and IFN-c were quantified as we described previously using a
MILLIPLEX MAP mouse cytokine/chemokine immunoassay kit
(EMD Millipore Corporation; Billerica, MA) and the Bio-Plex 200
system (Bio-Rad Laboratories GmbH, Munich, Germany) in
accordance with the manufacturers’ instructions [25].
Statistical analysis
The results were analyzed using the SigmaStat statistics
program (Systat Software, inc., San Jose, CA). Individual means
were compared using a non-paired Student’s t test or a Mann-
Whiney rank-sum test. Data derived from more than two groups
were compared by one-way analysis of variance (ANOVA)
followed by a Dunnett’s test to identify the groups that differed
significantly from the control (P,0.05).
Ethics Statement
Mice imported to Rhode Island Hospital were treated in
accordance with NIH publications entitled ‘‘Principles for Use of
Animals’’ and ‘‘Guide for the Care and Use of Laboratory
Animals’’ (8th Ed.) and an animal welfare protocol approved by
Rhode Island Hospital’s Animal Care and Use Committee
(Animal Welfare Protocol Committee number: 0256-11). Exper-
imental animals were monitored visually on a daily basis for signs
of distress that included hunching, ruffled fur, and impaired food
and water intake. Pain-free euthanasia at the termination of a
procedure was assured by carbon dioxide asphyxiation followed by
cervical dislocation.
Results
CD11c+PDCA-1+ vector DCs
Humanized, HLA-A2/DRB1 transgenic mice inoculated s.c.
with Flt3L-secreting B16 melanoma cells exhibited a 4- to 5-fold
increase in spleen cell number and a dramatic expansion of the
splenic DC population (Table 1 and Figure 2). The DC popula-
tion, enriched to <95% purity by positive selection using pan-DC
magnetic MicroBeads, was composed of conventional (c)DCs and
plasmacytoid (p)DCs. Both subsets were relatively immature,
evidenced by the minority of cells that expressed cell-surface HLA-
class II (DR1), CD40 and CD80 molecules. [Notably, mice
inoculated with Flt3L-secreting B16 melanoma cells also exhibited
a pronounced increase in size of the hepatic DC population
consisting of immature cDCs and pDCs (data not shown).]
Subsequently, the purified splenic DC population was transfected
by electroporation with NTC8685-eRNA41H-EGFP (GFP-ex-
pressing plasmid) in order to determine transfection efficiency.
Microscopic examination of the cells on the following day revealed
an approximate 60% transfection rate estimated visually (Fig-
ure 3).
DC vector-mediated vaccination against hepatitis C virus
The gene sequences that encode highly conserved HLA-
A*0201-restricted HCV epitopes and HLA-DRB1-restricted viral
ICS (validated previously by their ability to elicit specific naı¨ve
human T cell responses in vitro) were incorporated into two
separate multi-epitope genes, and each gene was cloned into an
expression vector (NTC8685-eRNA41H-EGFP). HLA-A2/DRB1
transgenic mice were immunized with these vaccine constructs
using DCs (characterized in the preceding section) as a vector.
DCs transfected with either of the two constructs were mixed in
equal proportion and the mice were immunized s.c. Mice
Figure 2. Purified CD11c+PDCA-1+ splenocytes. The total splenocyte population (left panel) derived from HLA-A2/DRB1 mice on day 12 post-
inoculation with FLT3L-secreting melanoma cells was enriched positive selection using pan-DC magnetic MicroBeads (middle panel) and
characterized by flow cytometry (right panel).
doi:10.1371/journal.pone.0104606.g002
Figure 3. HLA-A2/DRB1 DCs transfected by electroporation. Purified HLA-A2/DRB1 DCs were transfection by electroporation with a GFP-
expressing plasmid (NTC8685-eRNA41H-EGFP) and cultured overnight in the presence of GM-CSF to promote viability. The cells were examined
visually on the following day: UV microscopy (left), DAPI-counter stain (center), merged images (right).
doi:10.1371/journal.pone.0104606.g003
Epitope-Based HCV Vaccine
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administered non-transfected DCs served as the control. Spleno-
cytes derived from a group of four mice on day 35 following
immunization and a single boost 2-weeks later demonstrated a
negligible response to most peptides encoded by the vaccine
constructs in IFN-c ELISpot assays (data not shown). Splenocytes
derived from four mice vaccinated and boosted twice, however,
recognized and produced IFN-c in response to incubation with
,90% of the HLA-A2-restricted epitopes and all the HLA-DRB1-
restricted ICS (Figure 4). In both cases, the responses to individual
peptides quantified in ELISpot assays varied in terms of the
number of spots.
Vaccination favored Th1-type cytokine production by spleno-
cytes derived from vaccinated mice compared to mice inoculated
with non-transfected DCs. Though the response to individual
HLA-A2- and -DRB1-restricted peptides varied, the overall
production of pro-inflammatory cytokines (TNF-a and IFN-c)
was elevated significantly relative to the production of IL-4 and IL-
10 (Figure 5), Indeed, IL-4 production was barely detectable while
IL-10 production was often not increased relative to the control.
Discussion
New chemotherapeutic approaches that include NS3-4A
protease and/or NS5B polymerase inhibitors administered with
or without pegylated-interferon and ribavirin result in a significant
increase in the SVR found in patients infected with HCV
genotype 1 [7]. However, the adverse effects of therapy are often
severe, the costs are high, and a significant portion of those
patients treated remains infected [26]. Therapeutic vaccination
alone or in combination with drug treatment offers an additional
approach to treating chronic hepatitis C. Unfortunately, vaccina-
tion strategies undertaken to date have demonstrated varied and
only limited success in clinical trials [9,10]. Recombinant protein
vaccines, for example, are safe and well tolerated, but generally
ineffective due to their inability to induce CD8+ T cell responses.
Peptide-based HCV vaccines are similarly ineffective despite their
ability to elicit weak, epitope-specific CD8+ T cell responses and a
transient reduction in viral load in a minority of chronically
infected patients. Likewise, four out of six patients vaccinated with
a DNA construct that encoded conserved nonstructural (NS)3 and
NS4A peptide sequences exhibited an extremely modest reduction
in serum viral load [27]. Finally, attenuated viral vectors (e.g.,
adenovirus or modified vaccinia virus Ankara [MVA]) have been
used to boost the epitope-specific responses of CD4+ and CD8+ T
cells. Recombinant adenovirus that encoded the NS3–NS5 region
of HCV genotype 1B, for example, induced the sustained, multiple
epitope-specific T cell response of healthy volunteers [28].
However, only 8 of 15 chronically infected patients vaccinated
with MVA engineered to express HCV NS3-5b proteins exhibited
a reduction in viral load, and this reduction was transient [29].
Immunotherapy with HCV epitope-expressing DCs offers an
alternate, vector-mediated approach to treating chronic HCV-
infected patients; the results of a recent clinical trial document the
potential effectivity [12,13]. Vaccination induced the response of
CD8 T cells specific for six HLA-A2 restricted peptides expressed
by the DC vector; the response was transient, however, and the
effect on viral load was minimal. The goal of the present study was
to provide additional support for this approach, envisioning that
an increased range of HLA-A2-restricted epitopes and including
HLA-DRB1-restricted epitopes expressed by the vector would
improve the clinical outcome of vaccination. For this purpose, the
gene sequences encoding 38 highly conserved HCV epitopes/ICS
(identified previously and listed in Tables S1 and S2 in File S1)
were incorporated into two vaccine constructs that encoded either
HLA-A2- or –DRB1-restricted epitopes [14]. Subsequently,
immature DCs derived from humanized, HLA-A2/DRB1 (donor)
mice were transfected with these two constructs and the
transfected DCs were used to immunize HLA-A2/DRB1 (recip-
ient) mice. The vast majority of the epitopes encoded by these
constructs induced peptide-specific T cell recognition and the
production of TNF-a and IFN-c by immune splenocytes
(Figure 5). Both cytokines are principal mediators of anti-HCV-
specific T cell responses [30,31]. High-avidity, HLA-A2-restricted
T cells recovered from patients who cleared the virus exhibited
enhanced IFN-c and TNF-a production [31]. Moreover, CD4+
and CD8+ T cells obtained from healthy volunteers vaccinated
with two recombinant adenoviral vectors that encoded the NS3–
NS5 region of HCV genotype 1B secreted IFN-c and TNF-a [28].
In contrast to TNF-a and IFN-c, the epitope-specific produc-
tion of TH2-type cytokines (i.e., IL-4 and IL-10) by splenocytes
derived from vaccinated HLA-A2/DRB1 transgenic mice was
often non- or barely detectable. It is relevant to note in this regard,
that IL-10 typifies the progression to chronic liver disease in
patients infected with HCV [32]. Moreover, while IFN-c and
Figure 4. IFN-c ELISpot assays. The spleens were dissected and
pooled on day 35 from groups of 4 mice immunized with vaccine
construct-transfected, and IFN-c ELISpot assays were performed in
triplicate. The data, expressed as the means 6 SD ELISpots/106
splenocytes minus the average negative control, 0.1% DMSO+2 SD
(3,346 ELISpots/106 splenocytes), were obtained in a single experiment
representative of duplicate experiments. The average number of
ELISpots/106 splenocytes derived from mice immunized with non-
transfected DCs was not significantly different from the DMSO control
(not shown). *Splenocytes derived from mice immunized with
transfected DCs and incubated with the HLA-A2- and -DRB1-restricted
peptides indicated did not yield values that were significantly different
from the DMSO control (ANOVA).
doi:10.1371/journal.pone.0104606.g004
Epitope-Based HCV Vaccine
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Figure 5. Cytokine bead array. The spleens were dissected and pooled on day 35 from groups of four mice immunized with vaccine construct-
transfected or non-transfected DCs. Single cell suspensions were transferred to quadruplicate wells and cultured 40 hours in the presence of the
peptide indicated. The data, obtained in a single experiment representative of two experiments, are the means 6 SD pg/ml cytokine produced by
splenocytes obtained from mice immunized with transfected DCs minus that produced by splenocytes derived from control mice immunized with
non-transfected DCs. Concentrations of IFN-c, TNF-a, IL-4 and IL-10 (where indicated by *) are significantly greater than that produced by splenocytes
derived from control animals (P,0.05; Student’s t test or Mann-Whitney Rank Sums test).
doi:10.1371/journal.pone.0104606.g005
Epitope-Based HCV Vaccine
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TNF-a production is elevated, the production of IL-4 and IL-10
by T cells derived from patients who achieved a SVR to
chemotherapy is significantly diminished [33,34].
The response of regulatory T cells to certain epitopes derived
from structural, as well as non-structural, HCV proteins including
core, NS3 and NS5 is well documented [35–37]. Thus, peptide- or
epitope-based vaccine strategies that exclude such epitopes offer a
significant advantage over strategies that utilize intact HCV
proteins or vectors that encode whole proteins, which include
regulatory T cell epitopes and, consequently, can impede rather
than promote viral clearance. Interestingly, one HLA-DRB1-
restricted hepatitis C ICS (identified initially during screening, but
not included in the vaccine construct described herein) exhibited
extensive human homology and the ability to elicit the response of
regulatory T cells within the PBMC population derived from
HCV infected, but not non-infected, individuals (Losikoff et al.,
manuscript submitted). Furthermore, vaccination with DNA
constructs that express multiple viral epitopes, rather than the
epitopes/peptides themselves, circumvents any uncertainty re-
garding the longevity of epitope presentation [38].
Previously, we reported that human monocyte-derived DCs
pulsed with the same HLA-A2- and –DRB1-restricted peptide
sequences encoded by the vaccine constructs described herein
induced epitope-specific TNF-a and IFN-c production by naı¨ve
CD4+ and CD8+ human T cells ex vivio [14]. These results, taken
in conjunction with those reported here, support the therapeutic
potential of DCs expressing a broad array of HLA-A2- and –
DRB1-restricted epitopes in treating chronic, HCV-infected
patients. Clearly, however, any effort to demonstrate the efficacy
of a therapeutic vaccine against chronic hepatitis C is hampered
by the lack of a good, immunocompetent rodent model that
supports viral infection and replication [39]. Moreover, while
immunization with DCs that express an increased number of HLA
class I- and class II-restricted epitopes offers to improve vaccine
efficacy relative to that reported previously [12,13], such ex vivo
therapies suffer from a number of practical limitations including
the estimated high cost of treatment and a failure to elicit innate
immunity. As an alternative approach, we envision therapeutic
vaccination with a multiple HCV epitope-expressing DNA vector,
e.g., attenuated Listeria monocytogenes, that targets DCs in situ
and stimulates both innate and adaptive immunity [40]. Such a
vector-mediated, epitope-based vaccine offers an additional
approach to treating the expanding patient population affected
by chronic hepatitis C, as well as immunizing a non-infected
population at risk.
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